Global Cell And Gene Therapy CDMO Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Cell And Gene Therapy CDMO Market is presumed to reach the market size of nearly USD 29.39 BN by 2030 from USD 4.05 BN in 2022 with a CAGR of 28.11% under the study period 2023 - 2030.

Cell and Gene Therapy Contract Development and Manufacturing Organizations (CDMOs) are specialized companies that provide services for the development, manufacturing, and testing of cell and gene therapies on behalf of other biopharmaceutical companies. Cell and gene therapies are advanced therapeutic approaches that involve manipulating or engineering a patient's cells to treat or prevent diseases. These therapies hold great promise for various conditions, including certain cancers, genetic disorders, and other severe illnesses.

MARKET DYNAMICS

The Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) market is experiencing significant growth driven by multiple factors. The increasing focus and investment in cell and gene therapies as innovative treatments for various diseases have propelled the demand for specialized manufacturing services. The complexity of the manufacturing process involved in these therapies, coupled with the need for expertise and specialized facilities, has led to a rising trend of outsourcing to CDMOs. Regulatory support and compliance are critical drivers, as the stringent regulatory requirements for cell and gene therapies make experienced CDMOs with a proven track record in adherence to standards highly sought after. Flexibility and scalability offered by CDMOs are essential factors influencing the market, enabling biopharmaceutical companies to adapt production to clinical trial progress and commercialization needs effectively. As the field of cell and gene therapy advances, the demand for CDMO services is expected to continue growing, with these organizations playing a crucial role in supporting the development and manufacturing of innovative therapies.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of cell and gene therapy cdmo. The growth and trends of cell and gene therapy cdmo industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the cell and gene therapy cdmo market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Phase

Pre-Clinical
Clinical

By Product Type

Gene Therapy (Ex-Vivo, In-Vivo)
Gene-Modified Cell Therapy (Car T-Cell Therapies, Car-Nk Cell Therapy, Tcr-T Cell Therapy, Other)
Cell Therapy

By Indication

Oncology
Infectious Diseases
Neurological Disorders
Rare Diseases
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Cell And Gene Therapy CDMO market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Cell And Gene Therapy CDMO market include Lonza, Catalent, Inc, Cytiva, Samsung Biologics, Thermo Fisher Scientific Inc., Novartis AG, WuXi AppTec, AGC Biologics, OmniaBio, Rentschler Biopharma SE, Charles River Laboratories. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112113277

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . CELL AND GENE THERAPY CDMO - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Phase
- 3.7.2 Market Attractiveness Analysis By Product Type
- 3.7.3 Market Attractiveness Analysis By Indication
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL CELL AND GENE THERAPY CDMO MARKET ANALYSIS BY PHASE

5.1 Overview by Phase
5.2 Historical and Forecast Data
5.3 Analysis by Phase
5.4 Pre-clinical Historic and Forecast Sales by Regions
5.5 Clinical Historic and Forecast Sales by Regions

6 . GLOBAL CELL AND GENE THERAPY CDMO MARKET ANALYSIS BY PRODUCT TYPE

6.1 Overview by Product Type
6.2 Historical and Forecast Data
6.3 Analysis by Product Type
6.4 Gene Therapy (Ex-vivo, In-vivo) Historic and Forecast Sales by Regions
6.5 Gene-Modified Cell Therapy (CAR T-cell Therapies, CAR-NK Cell Therapy, TCR-T Cell Therapy, Other) Historic and Forecast Sales by Regions
6.6 Cell Therapy Historic and Forecast Sales by Regions

7 . GLOBAL CELL AND GENE THERAPY CDMO MARKET ANALYSIS BY INDICATION

7.1 Overview by Indication
7.2 Historical and Forecast Data
7.3 Analysis by Indication
7.4 Oncology Historic and Forecast Sales by Regions
7.5 Infectious Diseases Historic and Forecast Sales by Regions
7.6 Neurological Disorders Historic and Forecast Sales by Regions
7.7 Rare Diseases Historic and Forecast Sales by Regions
7.8 Others Historic and Forecast Sales by Regions

8 . GLOBAL CELL AND GENE THERAPY CDMO MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Data Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Data Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Data Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. South East Asia Sales Analysis
- 8.5.10. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Data Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Data Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE CELL AND GENE THERAPY CDMO COMPANIES

9.1. Cell And Gene Therapy Cdmo Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF CELL AND GENE THERAPY CDMO INDUSTRY

10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. Lonza
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. Catalent Inc
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Cytiva
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Samsung Biologics
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. Thermo Fisher Scientific Inc.
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. Novartis AG
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. WuXi AppTec
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. AGC Biologics
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. OmniaBio
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments
10.12. Rentschler Biopharma SE
- 10.12.1. Company Overview
- 10.12.2. Company Revenue
- 10.12.3. Products
- 10.12.4. Recent Developments
10.13. Charles River Laboratories
- 10.13.1. Company Overview
- 10.13.2. Company Revenue
- 10.13.3. Products
- 10.13.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies